|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0007102,
umls-concept:C0053932,
umls-concept:C0246694,
umls-concept:C0334227,
umls-concept:C1280500,
umls-concept:C1443643,
umls-concept:C1514873,
umls-concept:C1546857,
umls-concept:C1556066,
umls-concept:C1619636,
umls-concept:C1710082
|
|
pubmed:issue |
3
|
|
pubmed:dateCreated |
2008-5-26
|
|
pubmed:abstractText |
Inhibition of proteasome has been emerging as a promising approach in pathway-directed cancer therapy. Bone morphogenetic protein (BMP) signalling, which is known to be regulated by the ubiquitin-proteasome pathway in osteoblasts, plays a crucial role in the suppression of gastrointestinal carcinogenesis. Here we sought to elucidate the anti-mitogenic effect of a proteasome inhibitor in relation to BMP signalling in colon cancer.
|
|
pubmed:commentsCorrections |
http://linkedlifedata.com/resource/pubmed/commentcorrection/18414391-10073286,
http://linkedlifedata.com/resource/pubmed/commentcorrection/18414391-10224135,
http://linkedlifedata.com/resource/pubmed/commentcorrection/18414391-10458606,
http://linkedlifedata.com/resource/pubmed/commentcorrection/18414391-10762623,
http://linkedlifedata.com/resource/pubmed/commentcorrection/18414391-11040453,
http://linkedlifedata.com/resource/pubmed/commentcorrection/18414391-11381269,
http://linkedlifedata.com/resource/pubmed/commentcorrection/18414391-12782679,
http://linkedlifedata.com/resource/pubmed/commentcorrection/18414391-12821112,
http://linkedlifedata.com/resource/pubmed/commentcorrection/18414391-12850001,
http://linkedlifedata.com/resource/pubmed/commentcorrection/18414391-14685250,
http://linkedlifedata.com/resource/pubmed/commentcorrection/18414391-14699493,
http://linkedlifedata.com/resource/pubmed/commentcorrection/18414391-15378062,
http://linkedlifedata.com/resource/pubmed/commentcorrection/18414391-15655370,
http://linkedlifedata.com/resource/pubmed/commentcorrection/18414391-15690394,
http://linkedlifedata.com/resource/pubmed/commentcorrection/18414391-15958573,
http://linkedlifedata.com/resource/pubmed/commentcorrection/18414391-16314833,
http://linkedlifedata.com/resource/pubmed/commentcorrection/18414391-16340955,
http://linkedlifedata.com/resource/pubmed/commentcorrection/18414391-16409135,
http://linkedlifedata.com/resource/pubmed/commentcorrection/18414391-16769811,
http://linkedlifedata.com/resource/pubmed/commentcorrection/18414391-17151667,
http://linkedlifedata.com/resource/pubmed/commentcorrection/18414391-17317101,
http://linkedlifedata.com/resource/pubmed/commentcorrection/18414391-17919499,
http://linkedlifedata.com/resource/pubmed/commentcorrection/18414391-7624798,
http://linkedlifedata.com/resource/pubmed/commentcorrection/18414391-7877684,
http://linkedlifedata.com/resource/pubmed/commentcorrection/18414391-8649784,
http://linkedlifedata.com/resource/pubmed/commentcorrection/18414391-8653711,
http://linkedlifedata.com/resource/pubmed/commentcorrection/18414391-8774478,
http://linkedlifedata.com/resource/pubmed/commentcorrection/18414391-8831555,
http://linkedlifedata.com/resource/pubmed/commentcorrection/18414391-8878553,
http://linkedlifedata.com/resource/pubmed/commentcorrection/18414391-9018245,
http://linkedlifedata.com/resource/pubmed/commentcorrection/18414391-9215627,
http://linkedlifedata.com/resource/pubmed/commentcorrection/18414391-9335505,
http://linkedlifedata.com/resource/pubmed/commentcorrection/18414391-9461217,
http://linkedlifedata.com/resource/pubmed/commentcorrection/18414391-9649421
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jun
|
|
pubmed:issn |
0007-1188
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
154
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
632-8
|
|
pubmed:dateRevised |
2009-11-18
|
|
pubmed:meshHeading |
pubmed-meshheading:18414391-Adenocarcinoma,
pubmed-meshheading:18414391-Antineoplastic Agents,
pubmed-meshheading:18414391-Blotting, Western,
pubmed-meshheading:18414391-Bone Morphogenetic Proteins,
pubmed-meshheading:18414391-Cell Line, Tumor,
pubmed-meshheading:18414391-Colonic Neoplasms,
pubmed-meshheading:18414391-Cysteine Proteinase Inhibitors,
pubmed-meshheading:18414391-Fluorescent Antibody Technique,
pubmed-meshheading:18414391-Gene Expression Regulation,
pubmed-meshheading:18414391-Humans,
pubmed-meshheading:18414391-Leupeptins,
pubmed-meshheading:18414391-Phosphorylation,
pubmed-meshheading:18414391-Polymerase Chain Reaction,
pubmed-meshheading:18414391-RNA Interference,
pubmed-meshheading:18414391-Signal Transduction
|
|
pubmed:year |
2008
|
|
pubmed:articleTitle |
Bone morphogenetic protein signalling is required for the anti-mitogenic effect of the proteasome inhibitor MG-132 on colon cancer cells.
|
|
pubmed:affiliation |
Department of Medicine & Therapeutics, The Chinese University of Hong Kong, Hong Kong, China.
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|
